The NYSCF Array will cut down years of time and billions of dollars currently spent on drug development and clinical trials to ultimately accelerate the approval of new drugs and
therapies by regulatory agencies.
Not exact matches
The authors of the commentary emphasize that cell
therapies must be approved
by international and national
regulatory agencies and remain under the strict vigilance of health authorities.
These trials, unlike the unproven
therapies, have been approved
by the appropriate
regulatory agencies and will be rigorously tested so that the risks and benefits are more fully understood before (hopefully) being made available to patients.